Given the pivotal role of RTN3 and RTN4 in the modulation of BACE1 activity and generation of amyloid β in AD, inhibition of RTN3 aggregation appears to be a promising therapeutic strategy in the treatment of AD. The gene discussed is BACE1; the disease is Alzheimer disease.